OMG as a Marker of Resiliency to Neurodegenerative Processes
Large multi-cohort proteomics and genetic analyses identify circulating oligodendrocyte myelin glycoprotein (OMG) as inversely associated with cortical amyloid-β, dementia prevalence, and accelerated cognitive decline, with evidence that higher OMG drives axonal stability and proteostasis—supporting OMG as both a predictive biomarker and a potential neuroprotective therapeutic target.
Why it mattersLower plasma OMG predicts future dementia risk, so funders should prioritize OMG-targeted therapeutic programs.